An interventional study of intraocular lens implantation in Capsule Opacification, Pseudophakia and Cataract, sponsored by Medical University of Vienna. Completed. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2013-06-05.
Sponsored by Medical University of Vienna · Not applicable and Interventional
Age-related cataract is the main cause of impaired vision in the elderly population worldwide. In the UK, more than half of people who are over 65 have some cataract development in one or both eyes. The only treatment that can restore functional visual ability is cataract surgery where the opacified crystalline lens is removed by phacoemulsification and an artificial intraocular lens is implanted. It is estimated that around 10 million cataract operations are performed around the world each year. Cataract operations are generally very successful, with a low risk of serious complications. The most common risk is developing a condition called posterior capsule opacification (PCO), which causes impaired vision to return.
During the past two decades, cataract surgery underwent tremendous change and modernisation resulting in today's small incision phacoemulsification surgery and a safe technique with a short rehabilitation time for the patient. The most frequent long-term complication of cataract surgery remains to be posterior capsule opacification (PCO). In the past few years, refinements in surgical technique and modifications in IOL design and material have led to a decrease in the incidence of PCO.
It has been shown that a sharp posterior optic edge inhibits migration of lens epithelial cells (LEC) behind the IOL optic and therefore have a lower incidence of posterior capsule opacification (PCO). Most IOL designs have open-loop haptics that are connected to the optic towards the end of the production process, also called multipiece designs.
For several reasons such as better ease of use with injector systems and higher efficiency in the production process, companies have developed IOLs with open-loop haptics out of one block of material, also called single-piece designs. In the case of such single-piece IOLs, the haptics tend to be much thicker than with multipiece IOLs. A potential drawback of the thick haptics maybe an incomplete closure of the capsule at the optic rim with a reduced bending effect of the posterior capsule around the posterior optic edge. Additionally, the posterior sharp edge is often discontinuous in the region of the haptic-optic junctions. These locations may serve as a scaffold for LECs to migrate behind the IOL optic resulting in PCO. Nowadays a multitude of different single piece IOLS are available, many of them similar but of course with some differences in regard to the chemical composition of the acrylic material and the IOL design.
The purpose of this study is to compare the intensity of posterior capsule opacification (PCO) between two different 1-piece foldable hydrophobic acrylic intraocular lenses (IOLs) over a period of 3 years.
28 studies on the registry are indexed under Capsule Opacification; 2 are open to participants now.
This study's enrollment of 100 is above the median of 63 across 16 interventional studies indexed under Capsule Opacification.
Browse Capsule Opacification studies →Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
eyes with implantation of iMics1 NY-60 IOL
Procedure: intraocular lens implantation
eyes with implantation of AcrySof SN60WF IOL
Procedure: intraocular lens implantation
Posterior Capsule Opacification (PCO)
PCO = migration of lens epithelial cells behind the IOL optic after cataract surgery; scale 0-10 (0: no PCO; 10: maximum PCO)
Time frame: 3 years
Percentage of Eyes With Neodymium:Yttrium-aluminium-garnet (Nd:YAG) Capsulotomy
Treatment of PCO in neodymium:yttrium-aluminium-garnet (Nd:YAG) capsulotomy. The frequency of this treatment will be asseseed in percentage values
Time frame: 3 years
| Milestone | Patients Included |
|---|---|
| Started | 100 |
| Randomized | 100 |
| Allocation | 100 |
| Completed | 74 |
| Not completed | 26 |
| Withdrew: Death | 7 |
| Withdrew: Lost to follow-up | 14 |
| Withdrew: Chronical illness | 5 |
PCO = migration of lens epithelial cells behind the IOL optic after cataract surgery; scale 0-10 (0: no PCO; 10: maximum PCO)
| units on a scale (0-10) | iMics1 NY-60 | AcrySof SN60WF |
|---|---|---|
| Posterior Capsule Opacification (PCO) | 3.0 ± 2.0 | 1.9 ± 1.4 |
Treatment of PCO in neodymium:yttrium-aluminium-garnet (Nd:YAG) capsulotomy. The frequency of this treatment will be asseseed in percentage values
| percentage of eyes | iMics1 NY-60 | AcrySof SN60WF |
|---|---|---|
| Percentage of Eyes With Neodymium:Yttrium-aluminium-garnet (Nd:YAG) Capsulotomy | 26 ± 0 | 10 ± 0 |
Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| iMics1 NY-60 | — | 0/100 (0%) | 0/100 (0%) |
| AcrySof SN60WF | — | 0/100 (0%) | 0/100 (0%) |
| Age, Categorical(Participants) | Cataract Surgery |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 0 |
| >=65 years | 100 |
| Age Continuous(years) | Cataract Surgery |
|---|---|
| Mean | 72 ± 9 |
| Gender(participants) | Cataract Surgery |
|---|---|
| Female | 42 |
| Male | 32 |
| Region of Enrollment(participants) | Cataract Surgery |
|---|---|
| Austria | 100 |
No study locations are listed for this record.
This study is completed, as verified in Apr 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →